Search

Your search keyword '"Javier Menárguez"' showing total 2 results
Start Over Author "Javier Menárguez" Publisher ferrata storti foundation (haematologica)
2 results on '"Javier Menárguez"'

1. C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas

Author

Carmen Bellas, Paloma Martín-Acosta, Pilar Llamas, Federico Rojo, Manuela Mollejo, Rebeca Manso, Miguel A. Piris, Javier Menárguez, and Socorro María Rodríguez-Pinilla

Subjects
0301 basic medicine, PTCL, Poor prognosis, Biopsy, T cell, GATA3 Transcription Factor, Bioinformatics, Proto-Oncogene Proteins c-myc, 03 medical and health sciences, 0302 clinical medicine, GATA3, C-MYC, Medicine, Online Only Articles, Survival analysis, business.industry, Lymphoma, T-Cell, Peripheral, Hematology, Prognosis, Survival Analysis, Ki-67 Antigen, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cancer research, business, NODAL
Abstract

Funding: this study was supported by grants from the Asociacion Espanola contra el Cancer (AECC), Ministerio de Economia y Competitividad (MINECO) (SAF2013-47416-R), Instituto Salud Carlos III (ISCIII) – Fondos de Investigacion Sanitaria (RD06/0020/0107, RD012/0036/0060 and FIS11/1759). The Instituto de Investigacion Marques de Valdecilla (IDIVAL) is partly funded by the Sociedad para el Desarrollo Regional de Cantabria (SODERCAN)

Published
2016

2. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

Author

M. Carmen Ruiz-Marcellan, Miguel A. Piris, Eulogio Conde, Manuela Mollejo, Giovanna Roncador, Juan F. García, Carlos Montalbán, Santiago Montes-Moreno, Ana-Rosa Gonzalez-Medina, Javier Menárguez, Lorena Maestre, S M Rodríguez-Pinilla, and Lydia Sanchez-Verde

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Lymphoma, B-Cell, Plasma Cells, Biology, Immunophenotyping, Young Adult, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Plasma cell differentiation, PRDM1, medicine, Humans, B-cell lymphoma, Aged, Neoplasm Staging, Aged, 80 and over, PAX5 Transcription Factor, Large-cell lymphoma, Cell Differentiation, Hematology, Middle Aged, Antigens, CD20, medicine.disease, Immunohistochemistry, Survival Analysis, Lymphoma, Repressor Proteins, Treatment Outcome, Original Article, Female, Lymphoma, Large B-Cell, Diffuse, Positive Regulatory Domain I-Binding Factor 1, Diffuse large B-cell lymphoma, Plasmablastic lymphoma
Abstract

Background Plasmablastic lymphoma has recently come to be considered a distinct entity among mature B cell neoplasms, although the limits with diffuse large B-cell lymphoma (DLBCL) need to be more accurately defined.Design and Methods Here we show the results of an immunohistochemical study of 35 cases of plasmablastic lymphoma compared with a set of 111 conventional DLBCLs.Results Our results demonstrate that the use of a limited combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables the identification of a plasmablastic immunophenotype highly characteristic of plasmablastic lymphoma cases and associated with an aggressive clinical behavior. Additionally, the study shows that the acquisition of a partial plasmablastic phenotype (PRDM1/BLIMP1 expression) in DLBCL is associated with shorter survival in R-CHOP-treated patients.Conclusions The use of a restricted combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables a more accurate definition of terminal differentiation for large B-cell lymphoma.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results